Dr. Powles Discusses the Future of Durvalumab in Bladder Cancer

Thomas Powles, MD
Published: Tuesday, Mar 07, 2017



Thomas Powles, MD, Barts Cancer Institute, discusses the future of durvalumab in the treatment of bladder cancer.

In second-line therapy, the selective high-affinity human IgG1 monoclonal antibody durvalumab has shown compelling clinical activity, resulting in a jump directly to the frontline setting in clinical trials. This is ambitious, says Powles, but with frontline chemotherapy showing only modest results in bladder cancer, new therapies need to be tested.

Powles says there is a big chance that durvalumab could replace chemotherapy in the frontline, but combinations still need to be evaluated.
 


Thomas Powles, MD, Barts Cancer Institute, discusses the future of durvalumab in the treatment of bladder cancer.

In second-line therapy, the selective high-affinity human IgG1 monoclonal antibody durvalumab has shown compelling clinical activity, resulting in a jump directly to the frontline setting in clinical trials. This is ambitious, says Powles, but with frontline chemotherapy showing only modest results in bladder cancer, new therapies need to be tested.

Powles says there is a big chance that durvalumab could replace chemotherapy in the frontline, but combinations still need to be evaluated.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x